Search results
Two Philadelphia-area biotech firms report progress on pursuit of a hepatitis B cure - Philadelphia...
The Business Journals· 3 days agoTwo local life sciences companies reported progress this week on their efforts to develop a cure for...
Magistrate Sides With Defendants in Inmate's Claims in Failure to Treat Hep C | Law.com
Law.com· 6 days agoIn a memorandum opinion and recommendation issued May 28, Auld found that physician assistant Karen...
Opinion: Dr. Terry Lee was face of infectious disease expertise in Western North Carolina
Gannett via AOL· 2 hours agoWe pressed on as best we could, but Dr. Lee was impossible to replace. Our practice continued to...
‘Unusual’ cancers emerged after the pandemic. Doctors ask if covid is to blame.
Washington Post via Yahoo News· 2 days agoROCK HILL, S.C. - Kashyap Patel looked forward to his team’s Friday lunches. All the doctors from...
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus - Atea...
Benzinga· 4 days agoAtea Pharmaceuticals Inc AVIR announced Wednesday new data from the lead-in cohort (n=60) of the company’s ongoing Phase 2 combination study of bemnifosbuvir for hepatitis ...
Cost and Vosevi: How to find savings, lower costs, and more
Medical News Today· 6 days agoThe cost of the drug with and without insurance can depend on several factors, such as whether...
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress...
The Tomahawk· 2 days agoNew translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection
Humans and Neanderthals only had sex for a brief period, but it still fundamentally changed our DNA
Business Insider via Yahoo News· 2 days agoOther studies have linked Neanderthal genes to autoimmune diseases and diabetes. On the other hand,...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 days agoWith an 8-week treatment duration, the Phase 2 data from the lead-in cohort of non-cirrhotic patients showed a 97% sustained virologic response rate at 12 weeks post-treatment (SVR12), which ...
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Zacks· 2 days agoThis change outpaced the S&P 500's 0.11% loss on the day. Heading into today, shares of the HIV and hepatitis C drugmaker had lost 1.13% over the past month ...